Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis

Journal of Rheumatology

Volumn 23, Issue 9, 1996, Pages 1560-1564

  Storm, Tommy ^a,c   Kollerup, Gina ^a   Thamsborg, Gorm ^a   Genant, Harry K ^b   SØrensen, Ole H ^a  

^a AMAGER HOSPITAL   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAS Herlev ^*  (Denmark)

Author keywords

Bone mineral content; Etidronate; Fractures; Osteoporosis; Treatment

Indexed keywords

CALCIUM; CALCIUM GLUBIONATE; ETIDRONIC ACID; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; BONE DENSITY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; SPINAL FRACTURES; SPINE;

EID: 0029760406     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Storm T, Thamsborg G, Genant HK, Steiniche T, Sørensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-11.
2. Watts NB, Harris ST, Genant HK, et al: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
3. Harris ST, Watts NB, Jackson RK, et al: Four-year study of intermittent, cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:551-67.
4. Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH: Etidronate for postmenopausal osteoporosis. N Engl J Med 1990;323:1210.
5. Genant HK: Radiographic assessment of the effects of intermittent cyclical treatment with etidronate. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress ApS, 2047-54.
6. Genant HK, Wu CY, van Kuijk C, Nevitt MC: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48.
7. SAS Institute: SAS User's Guides: Statistics. Version 6.03. Cary, NC: SAS Institute, 1990.
8. Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD: Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporosis Int 1993;3:120-6.
9. Kanis J: Treatment of osteoporotic fracture. Lancet 1984;1:27-32.
10. Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Meisen F: A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 1989;10:313-20.
11. Liberman UA, Weiss SR, Bröll J, et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
12. Fleisch H: Bisphosphonates in Bone Disease: From the Laboratory to the Patient. Berne: Stämpli, 1993.
13. Lufkin EG, Argueta R, Whitaker MD, et al: Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994;4:320-2.
14. Maconi G, Porro GB: Ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-90.
15. Storm T, Steiniche T, Thamsborg G, Melsen F: Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 1993;8:199-207.
16. Steiniche T, Storm T, Thamsborg G, Sørensen HA, Melsen F: Histomorphometric evaluation of bone biopsies after long-term cyclical etidronate treatment. In: Christiansen C, Riis B, eds: Proceedings. Fourth International Symposium on Osteoporosis and Consensus Development Conference. Handelstrykkeriet Aalborg ApS, Denmark, 1993:137-8.